Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionMyeloperoxidase (MPO) inhibitor
Molecular Target Myeloperoxidase (MPO)
Mechanism of ActionMyeloperoxide (MPO) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard Indication Neurology (unspecified)
Indication DetailsTreat multiple system atrophy (MSA)
Regulatory Designation U.S. - Orphan Drug (Treat multiple system atrophy (MSA))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today